Dysregulated Immune and Metabolic Microenvironment Is Associated with the Post-Operative Relapse in Stage I Non-Small Cell Lung Cancer

Zhang, Shirong; Xiao, Xiao; Zhu, Xiuli; Chen, Xueqin; Zhang, Xiaochen; Xiang, Jingjing; Xu, Ruochen; Shao, Zhuo; Bai, Jing; Xun, Yunhao; Jiang, Yanping; Chen, Zhengzheng; Xia, Xuefeng; Jiang, Hong; Ma, Shenglin

doi:10.3390/cancers14133061

Cited by 4 publications

(3 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer mortality accounts for 27.05% and 22.42% of urban and rural tumour mortality, respectively [ 18 ]. Conventional chemotherapy has a 25% to 35% near-term remission rate for advanced non-small-cell lung cancer (NSCLC), a median survival time of 8 to 11 months, a one-year survival rate of only 30%, and an overall 5-year survival rate of less than 2% [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations

Song

Cheng

Zheng

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Objective. To investigate the need for and prognostic impact of gefitinib on the treatment of patients with early-stage epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC). Methods. Clinical data of patients with stage IB-IIA non-squamous non-small-cell lung cancer admitted to our thoracic surgery department from January 2020 to January 2022 were collected, and a total of 94 cases were included, divided into 44 cases in the control group (EGFR mutation-negative) and 50 cases in the experimental group (EGFR mutation-positive (including those on medication (19 cases) and those not on medication (31 cases)) according to the outcome of EGFR mutation. To evaluate the necessity and prognostic effect of gefitinib in the treatment of NSCLC patients with early EGFR mutations. Results. The lung cancer recurrence rate in the experimental group (66.00%) was higher than that in the control group (40.91%), and the difference was statistically significant ( χ 2 = 5.937, P = 0.015 ); in the subgroup analysis of the experimental group samples, the pharmacological intervention of gefitinib had a significant effect on lung cancer recurrence ( χ 2 = 7.797, P = 0.005 ), and the proportion of lung cancer recurrence in patients not taking the drug (80.65%) was significantly higher than in the drug-taking group (42.11%); the median survival time was 53.6 months using EGFR mutation type as the study factor, with a statistically significant difference in change in 5-year survival rate for EGFR mutation type ( χ 2 = 6.095, P = 0.047 ) and the lowest 5-year survival rate for subjects with EGFR mutation type Exon 20 T790M. Conclusion. Patients with early gene drive positive lung adenocarcinoma are significantly more likely to recur and metastasise and have shorter survival times in the absence of pharmacological intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations

Song

Cheng

Zheng

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…DNA-and RNA-based next-generation sequencing. Whole exome and transcriptome sequencing were performed in Geneplus-Beijing (Beijing, China) as previously described [27][28][29] . Brie y, genomic DNA and RNA were extracted from the tumor samples using FirePureTM FFPE gDNA Extraction Kit for genomic DNA and RNeasy FFPE Kit for RNA or AllPrep DNA/RNA FFPE Kit for both DNA and RNA (QIAGEN, Hilden, Germany).…”

Section: Methodsmentioning

confidence: 99%

Genomic and Transcriptomic Characterization of Pre-operative Chemotherapy Response in Patients with Osteosarcoma

Yang

Huang

Yuan³

et al. 2023

Preprint

View full text Add to dashboard Cite

Osteosarcoma is a heterogeneous disease with regard to its chemotherapy response and clinical outcomes. This study aims to investigate the genomic and transcriptomic characteristics related to pre-operative chemotherapy response. Samples from 25 osteosarcoma patients were collected to perform both whole exome and transcriptome sequencing. Osteosarcoma had the relatively high level of chromosomal copy number variant (CNV) burden. Chemotherapy responders showed the higher chromosomal CNV burden than non-responders (p = 0.0775). The percentage of COSMIC signature 3, associated with homologous recombination repair deficiency, was higher in responders (56%) than in non-responders (45%). Transcriptomic analysis suggested that 11 genes were significantly up-regulated in responders and 18 genes were up-regulated in non-responders. Both GSEA and KEGG enrichment analysis indicted that four pathways related to cardiomyopathy were up-regulated in responders, while neuroactive ligand−receptor interaction was up-regulated in non-responders. Finally, a random forest-based classifier was developed to classify chemotherapy response using 23 differentially expressed genes, with the area under the curve of 0.843 (95% CI, 0.654-1.000). Osteosarcoma had the heterogeneous mutational profile with frequent occurrence of CNVs. Transcriptomic analysis identified several signaling pathways associated with chemotherapy responsiveness to osteosarcoma. Transcriptomic characteristics classifier provides a potential research direction for predicting the chemotherapy response.

show abstract

“…Due to a scarcity in literature and lack of precise prognosis, improving the understanding of genetic markers is necessary. Here, we present two cases of PitNET undergoing genomic and transcriptomic analysis of tumour mass and peripheral blood by WES and RNA sequencing ( Chen et al, 2021 ; Zhang et al, 2022 ; Zhou et al, 2022 ). It was found that the overexpression of LAG3 and somatic mutations in DICER1 may be accountable for tumorigenesis and metastasis.…”

Section: Introductionmentioning

confidence: 99%

Case report: Identification of potential prognosis-related LAG3 overexpression and DICER1 mutation in pituitary carcinoma: two cases

Zhang,

Li,

Liu

et al. 2023

Front. Neurosci.

View full text Add to dashboard Cite

Metastatic PitNETs are a rare life-threatening condition with poor prognosis and documentation. Due to the scarce literature and lack of precise treatment, we hope to better characterise PitNET using the next-generation whole exon sequencing (WES) and RNA sequencing. This case study outlines a 54 years-old man and a 52 years-old woman who were both diagnosed with PitNET and analysis of peripheral blood and tumours were performed by WES and RNA sequencing. Analysis showed that DICER1 mutations in precancerous lesions and LAG3 overexpression were significant in aiding the prognosis and diagnosis of PitNETs. The first case with overexpressed LAG3 and DICER1 mutation died 26 months later, and the second case with LAG3 overexpression achieved partial remission. This study revealed that heightened expression of LAG3 offered promising targets for ICI and mutations in DICER1 could provide markers for effective diagnosis and prognosis.

show abstract

Dysregulated Immune and Metabolic Microenvironment Is Associated with the Post-Operative Relapse in Stage I Non-Small Cell Lung Cancer

Cited by 4 publications

References 53 publications

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations

Genomic and Transcriptomic Characterization of Pre-operative Chemotherapy Response in Patients with Osteosarcoma

Case report: Identification of potential prognosis-related LAG3 overexpression and DICER1 mutation in pituitary carcinoma: two cases

Contact Info

Product

Resources

About